AKT1 and non-small cell lung carcinoma: Then, an AKT specific inhibitor, MK2206 was used to co-treat NSCLC cells with BA and U0126, and immunoblotting revealed that MK2206 clearly abolished the activation of AKT caused by U0126 and BA in A549 and H1650 cells, respectively (Figure 5C).